Seattle, WA -- (SBWIRE) -- 11/07/2019 -- Alzheimer's disease (AD) is a type of neurological disorder that mainly affects thinking, memory, language, and behavior. This disease mainly occurs in people who are above 65 age and older and it has mild symptoms but results in severe brain damage in which individuals lose the ability to speak properly and respond to the environment.
According to the Alzheimer Association, 2017, more than 5.5 million Americans are suffering from Alzheimer's dementia. An estimated 5.3 million are age 65 and older and approximately 200,000 individuals are under age 65 and have the onset of Alzheimer's. Alzheimer's cognitive and behavioral symptoms can be treated by using non-drug treatment and symptomatic based medications. However, specific treatment for Alzheimer's disease is not available in the market, which creates an opportunity for the development of Anti- ?- Alzheimer therapies.
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1204
A breakthrough therapy is expected to offer immense growth for the Anti-?-Alzheimer therapies market
In July 2015, Biogen Pharmaceuticals announced results from a prespecified interim analysis of PRIME, which was the Phase 1b placebo-controlled study of aducanumab in patients with prodromal or mild Alzheimer's disease (AD). Phase I clinical trials were conducted on 166, patients, which showed significant progress by lowering of Amyloid beta levels in the brain and slowdown in cognitive function as compared to the control group who received a placebo. Phase III efficacy trial showed significant cognitive results in FDA based specific memory tests. On the other hand, in 2016, Eli Lilly and Company announced the development of Alzheimer's drug solanezumab, which was in phase III clinical trial due to its slow progression of Alzheimer's disease and high cost.
In 2012, Pfizer Inc. and Johnson & Johnson announced to discontinue the development of Alzheimer's drug which was in intravenous (IV) form – bapineuzumab as drug failed to help the patient with the memory-robbing condition in a second high profile clinical trial. Such failures, limit the growth of a market.
Rising prevalence and incidence of Alzheimer disease is projected to favor the growth of Anti-?-Alzheimer therapies market
A growing aging population along with its associated complications, such as dementia is the major driving factor for the growth of the Anti-?-Alzheimer therapies market. For instance, according to Centers for Disease Control and Prevention (CDC), 2013, five million Americans were suffering from AD and the number is expected to rise up to 14 million by 2050. Moreover, according to the World Health Organization (WHO), 2017, approximately 47 million people have dementia and nearly 10 million new cases are reported annually.
For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/1204
According to the Australian Bureau of Statistics (ABS) in 2013, dementia was the second leading cause of death in Australia. According to the Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach around 400,000 by 2020, and around 900,000 by 2050. The National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to priorities and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment and care for dementia patients. Rising prevalence and incidence of Alzheimer disease and its complication worldwide and growing demand for therapy is projected to favor the growth of Anti-?-Alzheimer therapies market in the near future.
Biogen Pharmaceuticals is a key player dominating the global Anti-?-Alzheimer therapies market.